儿科镰状细胞病治疗进展与未满足需求综述
Advances and Unmet Needs in Pediatric Sickle Cell Disease
该综述整合多位专家访谈,讨论美国儿科镰状细胞病生存率显著提升的原因与仍存在的临床缺口。新生儿筛查、预防性青霉素、疫苗接种及FDA批准药物的更广泛使用共同推动了中位预期寿命升至约60岁。
— It's better care that has led to better survival, not new treatment options
November 12, 2026 • 6 min read
As the 1970s came to a close, sickle cell disease (SCD) remained largely a pediatric condition because few children born in the U.S. with the condition survived to adulthood. Today, about 95% of children born with SCD in developed nations survive to adulthood. Median life expectancy in the U.S. has reached 60 years, meaning half of all patients live to that age, as compared with less than 40% just 10 years ago.
The dramatic improvement in survival evolved from an amalgamation of factors including universal screening of newborns, prophylactic penicillin to prevent bacterial infections, immunization against Haemophilus influenzae and Streptococcus pneumoniae, and broader and better-informed use of FDA-approved therapies for SCD. A recent multi-article review covered some of the key developments, as well as ongoing challenges and unmet needs.
Transformative Clinical Trials
Ironically, a clinical trial that did not meet its primary endpoint has profoundly influenced management of SCD. The randomized, placebo-controlled BABY HUG trial failed to show that hydroxyurea reduced the risk of kidney and spleen damage by 50% in very young children with SCD. Nonetheless, the trial showed that patients randomized to hydroxyurea had significantly fewer SCD-associated clinical events, including pain, dactylitis, acute chest syndrome, blood transfusion, and hospitalization. Investigators concluded that hydroxyurea "can now be considered for all very young children with sickle cell anemia."
BABY HUG was a landmark clinical trial because of the history of hydroxyurea, which was initially approved only for adults with SCD who met specific high-risk criteria. Published more than a decade ago, the trial established clinical principles that remain highly relevant today for children with SCD.
"[BABY HUG] gave us the evidence that hydroxyurea can be used as prevention, so before kids start having all these complications," Allison King, MD, MPH, PhD, of Washington University in St. Louis, told MedPage Today. "BABY HUG was really helpful because instead of being so reactive, the practice could be very proactive in pediatrics."
A recent analysis of more than 2,000 children with sickle cell anemia treated with hydroxyurea established long-term safety and efficacy. Children followed for as long as 8 years had significantly fewer and briefer hospitalizations, and laboratory data showed sustained improvement in hemoglobin in patients with good treatment adherence.
The Silent Cerebral Infarct Transfusion trial, published more than a decade ago, also had a transformative impact on SCD management. The results, in 200 children with sickle cell anemia, showed that regular blood transfusions significantly reduced the risk of silent cerebral infarction, which can have more subtle neurologic effects as compared with a stroke.
"A lot of our kids, and adults, have cognitive deficits, which are kind of like invisible disabilities because [the patients] can be quite verbal but have significant attention problems, processing speed, executive function that limit their ability to progress in their daily activities," said King. "Also, silent infarcts are a high risk for having overt strokes. Now it's an evidence-based guideline that we should be screening, as well as responding and transfusing, to prevent the progression."
Fast forward a decade and gene therapy became the next transformative clinical development in SCD, offering the potential for cure. Unfortunately, other therapeutic options for SCD have remained limited throughout the decade. One of the approved drugs, voxelotor (Oxbryta), was withdrawn from the market after post-approval data analysis and real-world clinical experience showed the benefits no longer outweighed the risks. Concern has arisen about the future status of another approved agent, crizanlizumab (Adakveo), which lost its conditional European marketing approval. Additionally, the drug failed to outperform placebo for reducing episodes of vaso-occlusive crisis in a recent phase III trial.
Moreover, cost and access remain major obstacles to expansion of gene therapy as a treatment option. In 2025, fewer than 200 patients worldwide received the two gene therapies, which come with a hefty price tag of $2-$3 million. Additionally, the process for screening and preparing patients for gene therapy can be "laborious" for many families, said King.
Ongoing Unmet Need
Despite the advances, more and more effective therapies are an ongoing need for patients with SCD, said Ofelia Alvarez, MD, of the University of Miami Health System.
"There is still a lot to do," she told MedPage Today. "The most widely used medication, hydroxyurea, does not work for all children with sickle cell anemia. Some patients do not respond. They continue to have low hemoglobin despite the treatment. We need new therapies to improve anemia, to decrease complications. They are always in need."
Better transitional care also has contributed to better survival in SCD. However, the quality of care and the ability to provide good transitional care vary greatly. Transition involves much more than handing off a patient from pediatric care to adult care, said Alvarez. Most young patients need to be educated about the disease itself, what medications are available and how they are used, and how to make appointments. Some need to learn about practical issues, such as budgeting, transportation, and learning to live independently.
"Here at the University of Miami, we have a very robust program that is co-created with patients and explained to the parents," said Alvarez. "After the transition, we follow up with the patients to see how they feel about the process and whether they have become integrated into the [adult] practice... . I personally don't have a lot of problems because I work very closely with the adult providers."
In some settings and circumstances, transition into adult care can be complicated and anything but a smooth process. The age at transition varies from practice to practice, but 18 is a common age. King, who specializes in caring for children, has expanded her patient age range up to 26. She described a 23-year-old patient whose circumstances are not rare in the SCD community.
"He has been intermittently homeless for 2 years," said King. "In his words, he 'couch surfs.' He doesn't have a stable place to live. He's not sure where he's getting his food. His meds are always being stolen, so he's frequently in the hospital for pain."
Understanding Pain
The case also illustrates the problem with using pain as a patient-reported endpoint for judging treatment efficacy, which has been a historical standard for the FDA.
"Pain is so multifactorial," said King. "It could be just sickling, and I'm not trying to minimize that, but it could be very biologically driven, but often, particularly in older teens and adults, psychosocial factors really are big drivers. That makes it difficult to tease out what's really driving a patient's pain."
Finding the origin of a patient's pain has been complicated by the fact that "for the last 20 years, we were sort of crawling our way out of the opioid crisis," said Jeffrey Glassberg, MD, of the Icahn School of Medicine at Mount Sinai in New York City.
"When I was in med school, we were taught that there was no danger to opioids," Glassberg told MedPage Today. "If you're treating pain, no harm could come to the patient. Today, I think most people who treat a lot of sickle cell patients would agree: Opioids cause pain. Full stop."
"We have noted that the more opioids that we were giving over the last couple of decades, the more pain our patients would experience, and that pain is non-vaso-occlusive," he continued. "Our latest research is really finding that patients feel that the pain is identical to vaso-occlusive crisis ... The more opioids you give, the more pain that patients will experience that's non-vaso-occlusive, but feels the same."
A number of candidate drugs for SCD have failed to pass muster with the FDA because they did not show a reduction in vaso-occlusive crises. Moving away from that as an endpoint for efficacy and toward a more objective endpoint -- such as organ damage -- might increase the likelihood of more drug approvals and more treatment options for patients, said Glassberg.
来源:MedPage Today · medpagetoday.com